KalVista Pharmaceuticals, Inc. (KALV) analyst actions
Rating and price-target actions on KALV in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the KALV overview →
1 measured KALV analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11 | Press release | +0.49% | +6.73% |
Keep exploring
More KALV: earnings → · SEC filings → · KALV overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EyePoint, Inc. (EYPT) | 439 | -0.25% | 46% |
| Abeona Therapeutics Inc. (ABEO) | 438 | +0.09% | 51% |
| Zymeworks Inc. (ZYME) | 438 | 0.00% | 50% |
| Exact Sciences Corporation (EXAS) | 437 | +0.08% | 56% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.